Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Neoplasms 12Breast Neoplasms 7Triple Negative Breast Neoplasms 5Ovarian Neoplasms 4Neoplasm Metastasis 4Unspecified Adult Solid Tumor, Protocol Specific 3Sarcoma 3Lymphoma 2Carcinoma, Non-Small-Cell Lung 2Relapsed Solid Tumors 1Refractory Solid Tumors 1Prostatic Neoplasms 1Metastatic Urothelial Cell Cancer 1Melanoma 1Lung Neoplasms 1Liposarcoma 1Fallopian Tube Neoplasms 1Colorectal Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1Advanced Solid Tumors 1

Interventions

Injections 18Carboplatin 14Docetaxel 11pembrolizumab 8durvalumab 7Cisplatin 6linifanib 5Paclitaxel 5Nivolumab 5zimberelimab 4talazoparib 4olaparib 4Panobinostat 4Itraconazole 4Bevacizumab 4tremelimumab 3sintilimab 3depatuxizumab 3atezolizumab 3ST 1481 3S 1 (combination) 3Rifampin 3Pemetrexed 3Oxaliplatin 3Fluorouracil 3Everolimus 3Drug Therapy 3trifluridine tipiracil drug combination 2trametinib 2toripalimab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Advanced Solid Tumors × eribulin × Clear all
NCT00908908 2012-03-09

A Study to Determine the Metabolism and Elimination of Carbon-14 Labeled Eribulin Acetate (14C-Eribulin) in Patients With Advanced Solid Tumors

Eisai Inc.

Phase 1 Completed
6 enrolled 7 charts
Other solid neoplasm

Advanced Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡